Middlebrooks CD, et al. - Researchers assessed the part played by the CDKN2A gene in patients with familial atypical multiple mole melanomas (FAMMM) Syndrome on age of onset for a number of cancers. They used 10 FAMMM syndrome families (N=1,085 individuals) and a mixed effects Cox regression for this analysis. Younger age of cancer onset was seen in carries vs non-carriers for FAMMM-related cancers as well as for newly associated cancers. Beyond the known cancers, CDKN2A mutation carriers in FAMMM syndrome families have higher risk for early onset of several cancer types, so screening of these candidates for additional cancers is recommended. Mutation screening should go beyond first-degree relatives of an index carrier case.